OpenLB
Open Library of Bioscience
Advanced Search
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
Jun, 2024;32 (6): 102072.

Formulation of silymarin surface modified vesicles: In vitro characterization to cell viability assessment.

Syed Sarim Imam, Sultan Owaid Alshammari, Sultan Alshehri, Wael A Mahdi, Mohamed H Al-Agamy
Author Information
  1. Syed Sarim Imam: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  2. Sultan Owaid Alshammari: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  3. Sultan Alshehri: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  4. Wael A Mahdi: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  5. Mohamed H Al-Agamy: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
PMID: 38726227 DOI: 10.1016/j.jsps.2024.102072

Abstract

Silymarin (SLR) is a poorly water-soluble bioactive compound with a wide range of therapeutic activities. Nanosized silymarin vesicles (F1-F6) were prepared by the solvent evaporation rehydration method. The silymarin vesicles were evaluated for vesicle size, surface charge, entrapment efficiency, and drug release studies. The optimized SLR lipid vesicle (F3) was further modified with the addition of the cationic polymer chitosan. After that, the modified vesicle (F3C1) was assessed for permeation flux, antimicrobial activity, cell viability, and molecular docking studies. The silymarin vesicles showed nanometric size (<250 nm), low polydispersibility index (<0.05), negative surface charge, and high SLR entrapment (85-95 %). The drug release study result demonstrated a maximum drug release of 91.2 ± 2.8 %. After adding chitosan to the surface, there was a significant change in the size, polydispersibility index, surface charge (positive), and encapsulation efficiency. The drug release was found to be prolonged, and the permeation flux was also increased in comparison to free SLR. A comparative antimicrobial result was observed in comparison to the free SLR and standard drug. The cell viability assay also demonstrated a low IC value for F3C1 against the cell line.

Keywords

Antimicrobial Cell line Chitosan Silymarin Vesicles

References

Biomed Pharmacother. 2002;56 Suppl 1:213s-216s [PMID: 12487285]
Pharmaceutics. 2022 Apr 21;14(5): [PMID: 35631495]
Molecules. 2021 Jun 17;26(12): [PMID: 34204251]
Biomed Pharmacother. 2021 Oct;142:112024 [PMID: 34399200]
Heliyon. 2023 Oct 05;9(10):e20657 [PMID: 37818003]
Pharmaceutics. 2022 Feb 26;14(3): [PMID: 35335895]
Int J Mol Sci. 2022 May 12;23(10): [PMID: 35628233]
Bioorg Med Chem Lett. 2002 Oct 21;12(20):2949-51 [PMID: 12270181]
Biomimetics (Basel). 2019 Apr 25;4(2): [PMID: 31105217]
Nanomedicine. 2017 Nov;13(8):2643-2654 [PMID: 28778838]
Planta Med. 2017 Oct;83(14-15):1184-1193 [PMID: 28472840]
Heliyon. 2021 Dec 24;8(1):e08674 [PMID: 35028457]
Biomed Pharmacother. 2016 Jul;81:93-103 [PMID: 27261582]
Int J Nanomedicine. 2011;6:1833-52 [PMID: 21931480]
AAPS PharmSciTech. 2017 Nov;18(8):3064-3075 [PMID: 28516414]
Molecules. 2023 Dec 21;29(1): [PMID: 38202640]
Molecules. 2019 Apr 30;24(9): [PMID: 31052197]
Food Res Int. 2019 Jun;120:656-667 [PMID: 31000284]
Pharmacol Rep. 2014 Oct;66(5):788-98 [PMID: 25149982]
Int J Nanomedicine. 2015 Oct 22;10:6633-44 [PMID: 26543366]
Life Sci. 2022 Oct 15;307:120908 [PMID: 36028168]
Pharmaceutics. 2022 Apr 05;14(4): [PMID: 35456629]
Pharm Dev Technol. 2019 Oct;24(8):927-934 [PMID: 30526167]
Int J Pharm. 2021 May 15;601:120571 [PMID: 33812967]
Food Chem. 2023 Dec 1;428:136680 [PMID: 37418880]
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):231-241 [PMID: 28503949]
Iran J Med Sci. 2023 May;48(3):321-328 [PMID: 37791331]
World J Gastroenterol. 2005 Sep 7;11(33):5136-41 [PMID: 16127742]
J Clin Pathol. 2011 Apr;64(4):343-8 [PMID: 21270061]
Pharmaceutics. 2017 Mar 27;9(2): [PMID: 28346375]
Mater Sci Eng C Mater Biol Appl. 2020 Oct;115:111117 [PMID: 32600716]
J Control Release. 2014 Sep 28;190:189-200 [PMID: 24818769]
Drug Deliv Transl Res. 2021 Feb;11(1):192-204 [PMID: 32394334]
Food Res Int. 2017 Oct;100(Pt 3):339-353 [PMID: 28964357]
Int J Pharm. 2006 Aug 17;319(1-2):121-9 [PMID: 16837151]
Food Bioproc Tech. 2023 Jun 13;:1-16 [PMID: 37363383]
Molecules. 2017 Jan 24;22(2): [PMID: 28125040]
Polymers (Basel). 2023 May 10;15(10): [PMID: 37242824]
J Control Release. 2004 Apr 16;96(1):135-48 [PMID: 15063036]
Pharmaceutics. 2023 May 17;15(5): [PMID: 37242757]
ACS Omega. 2020 Jun 30;5(27):16701-16710 [PMID: 32685837]
Gels. 2023 Feb 07;9(2): [PMID: 36826309]
Molecules. 2023 Feb 03;28(3): [PMID: 36771180]
J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X211068826 [PMID: 35018864]
Pharmaceutics. 2023 Feb 06;15(2): [PMID: 36839861]
J Nanobiotechnology. 2018 Sep 4;16(1):64 [PMID: 30176941]
Cancer Cell Int. 2021 Jun 24;21(1):318 [PMID: 34167552]
Int J Mol Sci. 2023 Jun 08;24(12): [PMID: 37373051]
Biomaterials. 2003 Mar;24(7):1121-31 [PMID: 12527253]
BMC Biotechnol. 2023 Aug 3;23(1):28 [PMID: 37537554]
Life Sci. 2021 Nov 1;284:119909 [PMID: 34450169]
BMC Complement Med Ther. 2023 Mar 4;23(1):69 [PMID: 36870998]
Biomedicines. 2023 Feb 04;11(2): [PMID: 36830989]
Nanomedicine (Lond). 2016 Oct;11(19):2581-602 [PMID: 27623396]
Int J Biol Macromol. 2019 Apr 1;126:662-672 [PMID: 30599159]
J Toxicol. 2011;2011:152474 [PMID: 21876690]
Cell Prolif. 2009 Apr;42(2):229-40 [PMID: 19317806]
Saudi Pharm J. 2019 Jul;27(5):603-611 [PMID: 31297013]
Journal Article

Word Cloud

Similar Articles

Cited By